Published in N Engl J Med on August 28, 2008
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One (2010) 2.24
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis (2010) 1.79
Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78
HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS (2010) 1.76
In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog (2010) 1.48
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 1.39
Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol (2009) 1.21
Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS (2011) 1.21
Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano (2013) 1.07
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol (2011) 1.05
Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clin Infect Dis (2010) 1.02
The fitness landscape of HIV-1 gag: advanced modeling approaches and validation of model predictions by in vitro testing. PLoS Comput Biol (2014) 1.02
Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J Virol (2010) 1.01
Novel directions in HIV-1 vaccines revealed from clinical trials. Curr Opin HIV AIDS (2013) 1.01
Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J Acquir Immune Defic Syndr (2010) 1.00
GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J Immunol (2010) 0.99
Understanding animal models of elite control: windows on effective immune responses against immunodeficiency viruses. Curr Opin HIV AIDS (2011) 0.98
Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology (2008) 0.97
A typology of structural approaches to HIV prevention: a commentary on Roberts and Matthews. Soc Sci Med (2012) 0.94
4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms. PLoS One (2010) 0.91
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91
Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res (2010) 0.90
A randomized trial of enhanced HIV risk-reduction and vaccine trial education interventions among HIV-negative, high-risk women who use noninjection drugs: the UNITY study. J Acquir Immune Defic Syndr (2010) 0.89
Immune-mediated attenuation of HIV-1. Future Virol (2011) 0.89
Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis (2011) 0.86
Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine. J Virol (2009) 0.85
Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med (2012) 0.85
Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles. PLoS Comput Biol (2010) 0.85
Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol (2011) 0.84
Applications and challenges of multivalent recombinant vaccines. Hum Vaccin Immunother (2012) 0.84
Vaccines, virucides and drugs against HIV/AIDS: hopes and optimisms for the future. Open AIDS J (2009) 0.83
Emerging studies of human HIV-specific antibody repertoires. Vaccine (2010) 0.81
Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccin Immunother (2013) 0.80
Association between specific HIV-1 Env traits and virologic control in vivo. Infect Genet Evol (2009) 0.79
Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy. Public Health Ethics (2012) 0.78
SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development? Curr HIV Res (2009) 0.78
Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Hum Antibodies (2012) 0.77
Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907. J Acquir Immune Defic Syndr (2016) 0.77
Can an immune-regulatory vaccine prevent HIV infection? Expert Rev Anti Infect Ther (2012) 0.75
The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases. PLoS Med (2009) 0.75
HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A (2002) 17.22
Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis (2008) 11.01
The challenge of emerging and re-emerging infectious diseases. Nature (2004) 8.94
Universal voluntary testing and treatment for prevention of HIV transmission. JAMA (2009) 7.20
Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med (2008) 5.14
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
The 1918 influenza pandemic: insights for the 21st century. J Infect Dis (2007) 4.99
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis (2008) 4.86
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance. J Infect Dis (2008) 3.84
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
An HIV vaccine--evolving concepts. N Engl J Med (2007) 3.78
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
The persistent legacy of the 1918 influenza virus. N Engl J Med (2009) 3.58
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis (2007) 3.50
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 3.47
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol (2008) 2.85
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Emerging infections: a perpetual challenge. Lancet Infect Dis (2008) 2.75
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep (2002) 2.70
Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis (2002) 2.57
Influenza vaccines for the future. N Engl J Med (2010) 2.54
Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci U S A (2006) 2.54
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA (2008) 2.45
Development of effective vaccines against pandemic influenza. Immunity (2006) 2.45
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis (2011) 2.40
Pathogenic mechanisms of HIV disease. Annu Rev Pathol (2011) 2.36
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med (2002) 2.36
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog (2011) 2.32
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis (2005) 2.12
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N Engl J Med (2016) 2.09
B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood (2010) 2.05
HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A (2007) 2.01
Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol (2008) 2.01
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 2.00
Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J Infect Dis (2012) 2.00
Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis (2003) 1.97
Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology (2009) 1.92
Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med (2010) 1.90
The next influenza pandemic: can it be predicted? JAMA (2007) 1.86
Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci U S A (2007) 1.82
Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem (2002) 1.79
Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis (2008) 1.79
Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood (2006) 1.73
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis (2012) 1.72
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72
What is a pandemic? J Infect Dis (2009) 1.69
Emerging infectious diseases: threats to human health and global stability. PLoS Pathog (2013) 1.65
CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro. AIDS Res Hum Retroviruses (2007) 1.64
HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS (2012) 1.59
Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med (2011) 1.56
Emerging infectious diseases: a clear and present danger to humanity. JAMA (2004) 1.55
Pandemic influenza's 500th anniversary. Clin Infect Dis (2010) 1.55
Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med (2011) 1.54
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis (2001) 1.54
Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A (2003) 1.53
Research funding. A framework for decisions about research with HPAI H5N1 viruses. Science (2013) 1.52
A way forward: the National HIV/AIDS Strategy and reducing HIV incidence in the United States. J Acquir Immune Defic Syndr (2010) 1.48
Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States. Ann Intern Med (2015) 1.47
Intradermal influenza vaccination--can less be more? N Engl J Med (2004) 1.47
Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS One (2007) 1.45
HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med (2011) 1.45
Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol (2003) 1.44
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog (2008) 1.44
Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev (2013) 1.38
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis (2004) 1.37
Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc Natl Acad Sci U S A (2006) 1.36
Chikungunya at the door--déjà vu all over again? N Engl J Med (2014) 1.32
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest (2014) 1.29
Pandemic influenza viruses--hoping for the road not taken. N Engl J Med (2013) 1.26
Smallpox vaccination policy--the need for dialogue. N Engl J Med (2002) 1.24
Asthma in the inner city: the perspective of the National Institute of Allergy and Infectious Diseases. J Allergy Clin Immunol (2010) 1.23
The United States President's Emergency Plan for AIDS Relief: a story of partnerships and smart investments to turn the tide of the global AIDS pandemic. J Acquir Immune Defic Syndr (2012) 1.23
Dengue research opportunities in the Americas. J Infect Dis (2012) 1.22
The 2009 H1N1 pandemic influenza virus: what next? MBio (2010) 1.22
CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV-infected individuals. J Immunol (2008) 1.21
HIV-1 vaccines and adaptive trial designs. Sci Transl Med (2011) 1.21
Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals. Proc Natl Acad Sci U S A (2004) 1.21
H7N9 avian influenza A virus and the perpetual challenge of potential human pandemicity. MBio (2013) 1.20
Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest (2011) 1.18
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med (2004) 1.18
HIV vaccine development--improving on natural immunity. N Engl J Med (2011) 1.16
Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis (2013) 1.15
Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. J Virol (2012) 1.15
Productive HIV infection of resting CD4+ T cells: role of lymphoid tissue microenvironment and effect of immunomodulating agents. AIDS Res Hum Retroviruses (2003) 1.14
IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa. Blood (2012) 1.14
R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proc Natl Acad Sci U S A (2006) 1.13
Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol (2011) 1.13
Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individuals. Proc Natl Acad Sci U S A (2007) 1.12
Identification of NKG2A and NKp80 as specific natural killer cell markers in rhesus and pigtailed monkeys. Blood (2005) 1.11
HIV envelope induces virus expression from resting CD4+ T cells isolated from HIV-infected individuals in the absence of markers of cellular activation or apoptosis. J Immunol (2003) 1.09
Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol (2006) 1.07
The perpetual challenge of antimicrobial resistance. JAMA (2014) 1.06